International generic name
Drug form and composition
Solution for injection. One ampoule of 2 ml contains 7.2 mg of Aminopyridine
hydrochloride (3,6 mg / 1 ml).
For elimination of the neuromuscular block, as an antagonist of the no depolarizing
muscle relaxants, as a component in the complex treatment of the Eaton-Lambert’s
syndrome, multiple sclerosis, Alzheimer’s disease, and myasthenia gravis. For ionophoresis
in physiotherapy in the treatment of neuralgia and neuritis of traumatic, infectious,
and toxic origin.
Dosage and administration
Pymadin is used as a slow injections or infusions with a rate of 0.25 mg/kg/h.
In patients suffering from multiple sclerosis, Pymadin can be administered intramuscularly
in a dose of 20 mg, bid. In patients with myasthenia gravis, the recommended dose
is 10 to 20 mg /24 hours, intravenously. For the elimination of the neuromuscular
block Pymadin is injected slowly intravenously in a dose of 30 mg (divided in 3
doses given in every 5 minutes intervals).
Pymadin is not used in conditions associated with an increased neuromuscular
excitability, severe liver or kidney diseases, hypersensitivity to this drug.
Special warnings and precautions
When the drug is used for the aims of decurarization in cases with bradicardia,
atropin should be given. In pregnant and breast-feeding women, Pymadin is used with
caution, in cases when the expected benefit exceeds the possible risk for the fetus
or the newborn. Because of the narrow therapeutic range of Pymadin a strict monitoring
and cautious increase in dosage are necessary. For reduction of the risk associated
with the high doses concurrent administration of anticonvulsants is recommended.
Pymadin has an antagonizing action to the ganglioblockers and to the oppressive
action on the CNS by the inhalation anesthetics. Concurrent administration with
galantamin leads to potentiation of the anti-curare action (particularly in cases
of intravenous infusion).
Headache, tremor; increased excitability, paresthesias; nausea; dry mouth; blood
pressure elevation; diaphoresis; and rarely allergic reactions can be observed in
By means of blocking the calcium channels of the cells Pymadin leads to: increased
acetylcholine release in the neuromuscular synapse (in the central and the peripheral
nervous system); increased sensitivity of the N-choline receptors in the striated
muscle to acetylcholine; augmentation of contractility of the skeletal muscle. The
central effects of Pymadin represent irritation of the respiratory and the vasomotor
center. The blood pressure elevation is a result of the excitation of the vasomotor
center and norepinephrine liberation by the sympathetic nerve ends in the arterial
vessel smooth muscle. The peripheral effects of this drug represent an augmentation
of neuromuscular transmission and hypertension. Pymadin possesses no anticholinesterase
10 or 100 ampoules of 2 ml (7.2 mg).